G42, OceanX, G-Tech and the Indonesian Government to Collaborate to Advance Oceanic Research to Protect the Marine Environment
18.11.2022 20:10:00 EET | Business Wire | Press release
G42, the leading UAE-based AI and cloud computing company and global nonprofit ocean exploration organization OceanX, along with G-Tech Digital Asia (G-Tech), and the Government of the Republic of Indonesia via its Coordinating Ministry for Maritime Affairs and Investment (CMMAI) have announced the signing of a Letter of Intent to establish a collaboration to develop ocean research to help protect the marine environment.
In furtherance of this proposed collaboration, G42 intends to deploy G42 Cloud’s large-scale cloud infrastructure and services, remote sensing drone systems by Bayanat, a public listed company at ADX in which G42 owns a majority stake, and cutting-edge marine genomics applications by G42 Healthcare in the support of OceanX’s social welfare mission and its world-class marine research and media vessel the R/V OceanXplorer, to conduct advanced, in-depth analysis of the coastal and oceanic environments.
The Letter of Intent was signed by Mohammad Firman Hidayat, Acting Deputy Coordinating Minister for Maritime Resources, Peng Xiao, Group CEO of G42, Vincent Pieribone, Vice Chairman of OceanX and Michel Hamilton, CEO of G-Tech.
The collaboration will support the aims of the Indonesian government, led by CMMAI, to improve management of marine resources including biodiversity and conservation of ecosystems, through the use of new technology and methodologies and OceanX’s broader mission to explore the ocean and bring it back to the world through educational media.
The project recognizes the importance of detailed mapping of marine resources through advanced technologies in order to protect and preserve the ocean environment and the livelihoods of the communities that are reliant on it. G42 will support OceanX and CMMAI research with a focus on mapping fisheries and marine resources through data-driven e-DNA, socio-economic, and ecological characters in coastal-marine ecosystems. The proposed collaboration also includes training and knowledge transfer to build human capacity and supporting infrastructure for CMMAI.
In line with the UAE’s mandate to explore and leverage advanced technologies to spearhead the efforts towards environmental preservation, G42 is deploying its extensive portfolio of companies to develop new and better ways in which both public and private organizations can address some of the most pressing climate and environmental challenges.
Peng Xiao, Group CEO of G42 commented: “We are proud to be collaborating with CMMAI and OceanX on this project to develop a greater understanding of Indonesia’s marine environment. Better data is vital to developing a more holistic view of our oceans’ condition, and through our work with OceanX, we are looking to support the development of new, tailored solutions and technologies that will help local authorities to protect the marine environment, for the benefit of present and future generations.”
Dr. Prashanth Marpu, Director of Geospatial Centre Of Excellence and Climate Action Program at Bayanat said: “Oceans are highly complex environments, and monitoring and research can present many challenges to researchers and scientists working in this field. Bayanat is applying its expertise in real-time geospatial services and solutions and handling large-scale data to develop the tools that will allow the research community to leverage big data analysis of the maritime environment.”
About G42
G42 is a global leader in creating visionary artificial intelligence for a better tomorrow. Born in Abu Dhabi and operating across the world, G42 champions AI as a powerful force for good. Its people are constantly reimagining what technology can do, applying advanced thinking and innovation to accelerate progress and tackle society’s most pressing problems.
G42 is driving change in the region and beyond, joining forces with nations, corporations and individuals to create the infrastructure for tomorrow’s world. From molecular medicine to space travel and everything in between, G42 realizes exponential possibilities, today.
For further information visit www.g42.ai.
About OceanX
Oceanographic Research & Exploration Foundation (OceanX) is a mission to support scientists to explore the ocean and to bring it back to the world through captivating media. Uniting leading media, science, and philanthropy partners, OceanX utilizes next-gen technology, fearless science, compelling storytelling, and immersive experiences to educate, inspire, and connect the world with the ocean and build a global community deeply engaged with understanding, enjoying, and protecting our oceans. OceanX is an initiative of Dalio Philanthropies, which furthers the diverse philanthropic interests of Dalio family members.
For more information visit www.oceanx.org and follow OceanX on Facebook, Instagram, Twitter, TikTok and LinkedIn.
About Bayanat
Bayanat, an ADX listed public company with majority shareholding by G42, provides comprehensive world-class AI-powered geospatial solutions to a growing number of sectors such as Defense, Environment, Energy & Resources, Smart Cities and Transportation. It’s offering includes topographic, hydrographic and aeronautical products and charts, as well as spatial data surveying, analysis, management, modelling, visualization and cartography services. Bayanat’s solutions harness vast amounts of premium and unique data from a range of sources including Satellites, High Altitude Pseudo Satellites (HAPS) and Earth Observation powered by AI to drive geospatial intelligence (gIQ).
For more information, please visit: www.bayanat.ai
Twitter:
https://twitter.com/bayanat_ai
LinkedIn:
https://www.linkedin.com/company/bayanatg42/
Instagram:
https://www.instagram.com/bayanat.g42/
Facebook:
https://www.facebook.com/bayanat.g42
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221118005443/en/
Contact information
For media enquiries, please send an email to: g42@trailrunnerint.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom